Custom service
Peptide Immunogen Phage Display Platform
Epitope-focused antibodies from chemically defined peptide antigens.
Some targets do not reward immunisation. Short peptides, disordered regions, linear epitopes buried in a folded domain and antigens that are toxic or difficult to express all produce weak or misdirected immune responses in animals. Phage display against a synthetic peptide returns antibodies aimed at an epitope you chose, not at whichever surface the animal happened to find immunodominant.
Two routes are used, and the choice is made on whether an antibody already exists. In the panning route, a peptide is immobilised and a naive or synthetic scFv/Fab library is panned against it over three to four rounds with increasing stringency. In the immunogen route, the peptide is displayed on filamentous phage as a fusion to the minor coat protein pIII, which turns a poorly immunogenic 10–20-mer into a repetitive, particulate antigen that readily activates B cells.
Both routes end in the same place: positive clones are sequenced, reformatted to human IgG1 or the required isotype, expressed in HEK293 and tested against the peptide and, where available, the full-length protein. An antibody that binds the peptide but not the native protein has failed, and we would rather report that than ship it.
Service Highlights
Where it fits
This platform suits anti-peptide reagents for proteomics and PTM detection, antibodies against linear epitopes of disordered proteins, and any project where the epitope must be specified in advance — a neutralising antibody against a fusion loop, or a capture antibody that must not compete with the detection antibody.
It is the wrong choice when the target epitope is conformational. A peptide cannot present a discontinuous surface, and no amount of panning will recover an antibody that needs the folded protein. For those targets we recommend whole-protein panning, cell panning or genetic immunisation instead.
Documentation and QC
Positive clones are sequence-verified in both directions, checked for frame integrity, and expressed before being reported. Binding is confirmed against the immunising peptide and against a scrambled peptide of identical composition; cross-reactivity to the full-length protein is reported as measured, including when it is absent.
Frequently asked questions
Will the antibody work in Western blot?
For linear epitopes, usually yes — peptide-raised antibodies are among the more reliable reagents for denaturing applications. We test by dot blot and, where the protein is available, by Western blot before delivery.
Can you pan against a peptide that is only 8 residues long?
Yes, though the smaller the peptide the higher the chance of cross-reactivity to similar sequences. A biotinylated 8-mer with a two-residue flank is workable; below that we would discuss a longer sequence or a different route.
Do you offer affinity maturation?
Yes. After the first round of panning, error-prone PCR or CDR-targeted mutagenesis libraries are built and re-panned under increased stringency, typically gaining five- to twenty-fold in KD.
Send the target sequence and tell us which region matters. We will confirm whether that epitope is reachable by peptide display, and say so plainly if a folded protein is needed instead.
Service Highlights
- Epitope selected by design. Peptide sequence, length and flanking residues are agreed before panning, so the resulting antibody recognises the region that matters for your assay.
- Synthetic libraries. Fully human scFv and Fab frameworks, with CDR3 diversity generated at the boundaries that contact antigen.
- Carrier-free options. Peptide synthesised with an N-terminal biotin or cysteine for oriented immobilisation, avoiding the lysine cross-linking that random coating produces.
- Panning with subtraction. Irrelevant peptide and streptavidin-only surfaces are used as negative selection to remove background binders before each round.
- Reformat to IgG. VH/VL from positive clones is cloned into human IgG1, IgG4, mouse IgG or Fab expression vectors.
- Peptide synthesis in house. Crude to >95% HPLC purity, with mass confirmation, phosphopeptides and cyclic peptides included.
How the work runs
Epitope and antigen design
Sequence, length, terminal modification and expected secondary structure are reviewed. Where the epitope sits at a protein interface, a longer peptide with native flanking sequence is preferred over a minimal core.
Peptide synthesis and QC
Solid-phase synthesis, HPLC purification and ESI-MS confirmation. Biotinylation is either on-resin at the N-terminus or on a single engineered cysteine, so the display orientation is fixed.
Library panning
Three to four rounds against streptavidin- or neutravidin-immobilised peptide, with monomeric peptide in solution as a competitive elution step from round two onward. Enrichment is followed by phage ELISA.
Screening and sequencing
Individual clones are screened by phage ELISA against the target peptide and a scrambled control; positives are sequenced and grouped by CDR3 to remove duplicates.
Reformatting and expression
Selected VH/VL pairs are cloned into the requested backbone, expressed in HEK293 and purified by protein A or affinity chromatography.
Binding characterisation
ELISA and BLI against peptide and full-length protein, with affinity constants where the interaction is strong enough to measure.
Specifications & timeline
- Library size
- 10⁹–10¹⁰ — independent clones
- Timeline
- 5–7 weeks — from peptide to IgG
- Format
- scFv / Fab — convertible to full IgG
- Library format
- Human naive scFv/Fab, ~10⁹–10¹⁰ clones; synthetic CDR libraries on request
- Peptide length
- 8–30 residues, linear or cyclic; phospho-, acetyl- and methyl-peptides available
- Panning rounds
- 3–4, with competitive elution from round 2
- Affinity range
- Typically 10⁻⁷–10⁻⁹ M from naive libraries; affinity maturation available
- Timeline
- 5–7 weeks for panning, screening and IgG expression
- Deliverables
- Sequence, 0.1–1 mg purified IgG, ELISA and BLI data, phage clone archive
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.